一个预测性毒动力学模型,用于从血管支架中出水
Matheos Giakoumi1, Pavlos S Stephanou2, Despoina Kokkinidou1
1Department of Mechanical Engineering and Materials Science and Engineering, Cyprus University of Technology, Limassol 3036, Cyprus.
ACS biomaterials science & engineering
|March 25, 2024
概括
基于生理学的毒动力学 (PBTK) 模型预测了植入物中的金属离子出. 这项研究开发了血管支架的PBTK模型,准确评估患者对离子的暴露,并确保监管合规.
科学领域:
- 生物医学工程 生物医学工程
- 毒理学 毒理学 毒理学
- 材料科学 材料科学 材料科学
背景情况:
- 医学植入物的体外测试在预测体内性能方面是有限的.
- 了解植入物腐蚀和离子漏对于患者安全至关重要.
- 目前的方法很难量化副产品的生物分布和患者的暴露.
研究的目的:
- 为血管支架开发一种基于生理学的毒动力学 (PBTK) 模型.
- 量化评估离子浸出和患者因植入器件暴露的情况.
- 为医疗植入物推进非临床测试方法.
主要方法:
- 创建了一个多隔间PBTK模型来模拟离子转移.
- 模型参数化使用沉浸试验和动物植入研究.
- 使用蒙特卡洛方法的模拟引擎估计了离子度-时间概况.
主要成果:
- 该PBTK模型准确地预测了来自血管支架的离子泄.
- 模拟表明预后符合实验数据.
- 该模型有效地评估了潜在的暴露极限超值.
结论:
- PBTK模型为医疗植入物风险评估提供了一个强大的工具.
- 这种PBTK模型可以指导更安全的植入式设备的设计.
- 建模和模拟可以支持医疗植入物的监管合规性.
更多相关视频
09:23Removal of Trace Elements by Cupric Oxide Nanoparticles from Uranium In Situ Recovery Bleed Water and Its Effect on Cell Viability
Published on: June 21, 2015
9.8K
08:25Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure
Published on: June 5, 2020
6.7K
相关概念视频
01:20Pharmacokinetic Models: Overview
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).